Skip to main
AVTX

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics (AVTX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avalo Therapeutics is a biotechnology company with a strong focus on developing innovative treatments for immune-mediated inflammatory diseases. With a solid balance sheet and recent successful trial results for their lead product, AVTX-009, the company is well-positioned for future growth. However, risks exist, including potential clinical and regulatory failures and the need for additional funding to support commercialization efforts. Overall, the positive Phase 2 results and strong financial position make Avalo Therapeutics a promising investment opportunity.

Bears say

Avalo Therapeutics is a clinical stage biotechnology company specializing in developing IL-1B-based treatments for immune-mediated inflammatory diseases. While their pipeline includes multiple promising candidates, their recent Phase 2 LOTUS trial data for Abdakibart (AVTX-009) did not definitively demonstrate superiority over competitor drugs in the same class, leading us to question its potential for dominating the market. Additionally, the company's financials, while improved from the previous quarter, show limited growth opportunities and a high level of risk involved in their development plans.

Avalo Therapeutics (AVTX) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avalo Therapeutics (AVTX) Forecast

Analysts have given Avalo Therapeutics (AVTX) a Buy based on their latest research and market trends.

According to 8 analysts, Avalo Therapeutics (AVTX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avalo Therapeutics (AVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.